{
    "name": "isatuximab",
    "comment": "Rx",
    "other_names": [
        "Sarclisa",
        "isatuximab-irfc"
    ],
    "classes": [
        "Antineoplastics",
        "Anti-CD38 Monoclonal Antibodies"
    ],
    "source": "https://reference.medscape.com/drug/sarclisa-isatuximab-4000022",
    "pregnancy": {
        "common": [
            "Based on the mechanism of action, fetal harm may occur when isatuximab is administered to a pregnant woman",
            "No data available on use in pregnant women to evaluate drug-associated risks",
            "Animal reproduction toxicity studies have not been conducted"
        ],
        "specific": [
            {
                "type": "Clinical considerations",
                "description": []
            },
            {
                "type": "Contraception",
                "description": [
                    "Females: advise females of reproductive potential to use effective contraception during treatment and for at least 5 months after the last dose",
                    "Also see prescribing information for pomalidomide for further information"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Data not available on presence of isatuximab in human milk, on milk production, or effects on the breastfed child",
            "Maternal IgF is known to be present in human milk; effects of local gastrointestinal exposure in the breastfed infant are unknown",
            "Advise lactating women not breastfeed during treatment",
            "Refer to the prescribing information of pomalidomide and dexamethasone for further recommendations"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Severe hypersensitivity to isatuximab or to any of its excipients"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Neutropenia reported; monitor complete blood cell counts periodically; consider antibiotics and antiviral prophylaxis during treatment; if grade 4 neutropenia occurs, delay dose until neutrophil count recovery to at least 1 x 10",
                "9",
                "/L, and provide supportive care with growth factors, according to institutional guidelines",
                "Second primary malignancies (SPMs) reported; monitor for the development of SPM, as per International Myeloma Working Group guidelines",
                "Can cause fetal harm"
            ],
            "specific": [
                {
                    "type": "Infusion-related reactions",
                    "description": [
                        "Serious infusion-related reactions including life-threatening anaphylactic reactions have occurred with treatment; severe signs and symptoms have included cardiac arrest, hypertension, hypotension, bronchospasm, dyspnea, angioedema, and swelling",
                        "All infusion-related reactions started during the first infusion and resolved within the same day",
                        "Premedicate before infusion to decrease the risk and severity of the reactions; monitor vital signs frequently during the entire infusion",
                        "For Grade 1 or 2 reactions, interrupt infusion and provide appropriate medical support",
                        "If symptoms improve, restart infusion and reduce rate by half, with supportive care as needed, and closely monitor",
                        "If symptoms do not recur after 30 min, then increase infusion rate to the initial rate, and then increase incrementally",
                        "In case symptoms do not improve or recur after interruption, permanently discontinue and institute appropriate management",
                        "Permanently discontinue therapy if a grade 3 or higher infusion-related reaction occurs and institute appropriate medical management"
                    ]
                },
                {
                    "type": "Drug interaction overview ",
                    "description": [
                        "Serological testing (indirect antiglobulin test)",
                        "Isatuximab binds to CD38 on red blood cells (RBCs) and may result in a false-positive indirect antiglobulin test (indirect Coombs test)",
                        "Type and screen patients before starting treatment",
                        "Inform blood bank that the patient is receiving isatuximab",
                        "If an emergency transfusion is required, non-cross-matched ABO/RhD-compatible RBCs can be given as per local blood bank practices",
                        "Serum protein electrophoresis and immunofixation tests",
                        "Isatuximab is an IgG kappa monoclonal antibody that can be incidentally detected on both serum protein electrophoresis and immunofixation assays used for clinical monitoring of endogenous M-protein",
                        "This interference may affect the accuracy of the determination of complete response in some patients with IgG kappa myeloma protein"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Anemia",
            "percent": "99"
        },
        {
            "name": "Neutropenia",
            "percent": "96"
        },
        {
            "name": "Lymphopenia",
            "percent": "92"
        },
        {
            "name": "Thrombocytopenia",
            "percent": "84"
        },
        {
            "name": "Upper respiratory tract infection",
            "percent": "57"
        },
        {
            "name": "Infusion",
            "percent": "38"
        },
        {
            "name": "related reactions",
            "percent": "31"
        },
        {
            "name": "Pneumonia",
            "percent": "26"
        },
        {
            "name": "Diarrhea",
            "percent": "17"
        },
        {
            "name": "Dyspnea",
            "percent": "15"
        },
        {
            "name": "Nausea",
            "percent": "12"
        },
        {
            "name": "Vomiting",
            "percent": "12"
        },
        {
            "name": "Febrile neutropenia",
            "percent": "24-61"
        },
        {
            "name": "Neutropenia",
            "percent": "13-42"
        },
        {
            "name": "Lymphopenia",
            "percent": "32"
        },
        {
            "name": "Anemia",
            "percent": "3.3-22"
        },
        {
            "name": "Pneumonia",
            "percent": "14-16"
        },
        {
            "name": "Thrombocytopenia",
            "percent": "1.3-11"
        },
        {
            "name": "Febrile neutropenia",
            "percent": "9"
        },
        {
            "name": "Upper respiratory tract infections",
            "percent": "5"
        },
        {
            "name": "Dyspnea",
            "percent": "2"
        },
        {
            "name": "Diarrhea",
            "percent": "1.3"
        },
        {
            "name": "Infusion",
            "percent": "1.3"
        },
        {
            "name": "related reactions",
            "percent": null
        },
        {
            "name": "Vomiting",
            "percent": null
        }
    ]
}